Abstract:Introduction: The repertoire of microRNAs (miRNAs) in thyroid carcinomas starts to be elucidated. Among differentiated thyroid carcinomas (DTCs), papillary thyroid carcinoma (PTC) is the most frequent. The assessment of miRNAs expression may contribute to refine the pre-surgical diagnosis in order to obtain a personalized and more effective treatment for patients. Aims: This study aims to evaluate (1) the miRNAs in a series of DTCs, and their association with the presence of selected genetic mutations in order to improve diagnosis and predict the biologic behavior of DTC/PTC. (2) The reliability of molecular tests in Ultrasound-guided Fine Needle Aspiration Cytology (US-FNAC) for a more precise preoperative diagnosis. Material and Methods: This series includes 176 samples (98 cytology and 78 histology samples) obtained from 106 patients submitted to surgery, including 13 benign lesions (controls) and 93 DTCs (cases). The microRNA expression was assessed for miR-146b, miR-221, miR-222, and miR-15a through quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). The results were analyzed by the 2−ΔΔCT method, using miR16 as an endogenous control. Regarding PTC diagnosis, the discriminative ability of miRNAs expression was assessed by the area under the Receiver Operating Characteristic Curve (AUC). In PTCs, the association of miRNAs expression, clinicopathological features, and genetic mutations (BRAF, RAS, and TERTp) was evaluated. Results/Discussion: All the analyzed miRNAs presented a tendency to be overexpressed in DTCs/PTCs when compared with benign lesions, both in cytology and histology samples. In cytology, miRNAs expression levels were higher in malignant tumors than in benign tumors. In histology, the discriminative abilities regarding PTC diagnosis were as follows: miR-146b (AUC 0.94, 95% CI 0.87–1), miR-221 (AUC 0.79, 95% CI 0.68–0.9), miR-222 (AUC 0.76, 95% CI 0.63–0.89), and miR-15a (AUC 0.85, 95% CI 0.74–0.97). miR-146b showed 89% sensitivity (se) and 87% specificity (sp); miR-221 se = 68.4, sp = 90; miR-222 se = 73, sp = 70; and mi-R15a se = 72, sp = 80. MicroRNAs were associated with worst-prognosis clinicopathological characteristics in PTCs (p < 0.05), particularly for miR-222. Our data reveal a significant association between higher expression levels of miR-146b, miR-221, and miR-222 in the presence of the BRAF mutation (p < 0.001) and miR-146b (p = 0.016) and miR-221 (p = 0.010) with the RAS mutation, suggesting an interplay of these mutations with miRNAs expression. Despite this study having a relatively small sample size, overexpression of miRNAs in cytology may contribute to a more precise preoperative diagnosis. The miRNAs presented a good discriminative ability in PTC diagnosis. The association between the miRNAs expression profile and genetic alterations can be advantageous for an accurate diagnosis of DTCs/PTCs in FNAC.

Expressions of Mirnas in Papillary Thyroid Carcinoma and Their Associations with the BRAFV600E Mutation and Clinicopathological Features

Expression Profile And Clinical Significance Of Micrornas In Papillary Thyroid Carcinoma

Expressions of Mirnas in Papillary Thyroid Carcinoma and Their Associations with the Braf(V600e) Mutation

Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer

Expression of Mirnas in Papillary Thyroid Carcinomas is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients.

Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma.

The Combined Use Of Mirnas And Mrnas As Biomarkers For The Diagnosis Of Papillary Thyroid Carcinoma

Integrated Analyses of Microrna and Mrna Expression Profiles in Aggressive Papillary Thyroid Carcinoma

Upregulation of Mir-2861 and Mir-451 Expression in Papillary Thyroid Carcinoma with Lymph Node Metastasis

Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas

BRAFV600E mutation and NIS expression in papillary thyroid carcinomas

Expression Profiles of Micrornas and Their Target Genes in Papillary Thyroid Carcinoma

Association of Mirna Expression and EGFR Mutation Status in Lung Adenocarcinomas.

Combination of Serum Micrornas and Ultrasound Profile As Predictive Biomarkers of Diagnosis and Prognosis for Papillary Thyroid Microcarcinoma.

MicroRNA Profiling in Papillary Thyroid Cancer

Mirna-106A Directly Targeting RARB Associates with the Expression of Na + /I − Symporter in Thyroid Cancer by Regulating MAPK Signaling Pathway

Expression level of miR-146 b-5 p via miRNA sequencing and its potential targets in papillary thyroid cancer

Expression of miR-2 2 1 and miR-2 2 2 in Papillary Thyroid Carcinoma Tissues and Its Clinical Significance

Aberrant expression of five miRNAs in papillary thyroid carcinomas

Identification of Key Mrnas, Mirnas, and Mrna-Mirna Network Involved in Papillary Thyroid Carcinoma

Mir-3619-3p Promotes Papillary Thyroid Carcinoma Progression Via Wnt/β-catenin Pathway